Selecta/JDRF Collaboration Seeks Vaccine To Prevent Or Treat Type 1 Diabetes
This article was originally published in The Pink Sheet Daily
JDRF will provide milestone-based financial support toward preclinical proof of concept for a tolerogenic vaccine candidate.
You may also be interested in...
Deals of the Week: Sanofi/Selecta, Evotec/Probiodrug, Nestle/Chi-Med…
European economists meeting in London discuss drug innovation’s costs to the larger health system, research funding sources, and “sin taxes.”
Sanofi And Selecta To Partner On Immunotherapies For Life-Threatening Allergies
Vaccine and immunotherapy-focused Selecta, up to now focused on grants for funding, signs its first big pharma partner around targeted, antigen-specific programs for undisclosed allergies.
Deals Of The Week: Upsher-Smith/Proximagen, Novo Nordisk/JDRF, Newron/NeuroNova
With BIO 2012 taking place June 17-21, the entire health care world awaits the Supreme Court’s ruling on health care reform. In the pharma world, companies are strategizing against all the possible outcomes.